Corrections to the last section (''Survival'') on page 1582:
. Overall survival at 1 year was 42% for TACE subjects compared to 46% for TARE. Statistically there was no difference noticed between 2 modalities (RR = 0.93, 95% CI 0.81-1.08, p = 0.33). At 2 years more TACE patients were alive than those that received TARE (27 vs. 18%) the difference of which was statistically significant (RR = 1.36, 95% CI 1.05-1.76, p = 0.02). At 3 years more TACE patients survived (14 vs. 8%) yet no statistically significant difference was noted (RR = 1.27, 95% CI 0.88-1.84, p = 0.20). At 4 years subjects alive from both TACE and TARE were 4% with no statistically significant difference in survival (RR = 1.64, 95% CI 0.80-3.34, p = 0.17). At 5 years only 1% of subject population was alive from both TACE and TARE treatment modalities. There was minimal heterogeneity among studies (p [ 0.05). Disease-specific mortality (RR = 1.58, 95% CI 0.49-5.10, p = 0.44) did not show difference between studies but high heterogeneity was noted (p2 = 0.6462, p = 0.0015, I2 = 90%). 
